Results 251 to 260 of about 77,075 (344)

658 Intra-cavitary tocilizumab immunotherapy for malignant pleural effusions and ascites: in progress update from the regional immuno-oncology trial (RIOT)-2 [PDF]

Patrick Wagner, Hyun Young Park, Rose J Blodgett, Vera S. Donnenberg, Catherine R Lewis, Neda Dadgar, Kunhong Xiao, Ali H. Zaidi, David L. Bartlett, Albert D. Donnenberg   +9 more
openalex   +1 more source

Long-term outcomes after pleural decortication for patients with chronic sterile, non-malignant pleural effusion. [PDF]

J Thorac Dis
Yang HC, Drysch A, Kurihara C, Schraufnagel DP, Kim SS, Bharat A, Lung KC.   +6 more
europepmc   +1 more source

Malignant pleural effusion. [PDF]

Thorax, 1995
openaire   +1 more source

Frontline ATRA‐ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG‐APL2017 Trial

Cancer Science, Volume 117, Issue 4, Page 1117-1123, April 2026.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, Koji Yonemoto, Mine Harada, Koichi Akashi, Toshihiro Miyamoto   +14 more
wiley   +1 more source

Microfilarae in malignant mesothelioma associated pleural effusion with blood microfilaremia: a rare association

, 2019
Dinesh C Sharma, Deepanjali Sharma
openalex   +2 more sources

Optimizing tissue sampling during medical pleuroscopy for diagnosis of malignant pleural effusion due to lung cancer. [PDF]

Sci Rep
Lojo-Rodríguez I, Botana-Rial M, González-Piñeiro A, Cases-Viedma E, González-Montaos A, Ramos-Hernández C, Nuñez-Delgado M, Fernández-Villar A.   +7 more
europepmc   +1 more source

Impact of Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors on Anti‐PD‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Cancer Science, Volume 117, Issue 4, Page 929-942, April 2026.
Ramucirumab (RAM) plus docetaxel (DOC) after PD‐1 inhibitors showed clinical activity, with responders exhibiting maintained anti–PD‐1 (IgG4+)‐bound CD8+ T cells and decreased IgG4+ Tregs. A sequential strategy of administering RAM plus DOC during persistent anti–PD‐1 antibody binding may be beneficial in patients with advanced non‐small cell lung ...
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori, Shingo Satoh, Hidekazu Suzuki, Satoshi Tetsumoto, Toshie Niki, Yasuhiko Suga, Akio Osa, Toshiyuki Minami, Shohei Koyama, Yoshito Takeda, Nobuyuki Takakura, Atsushi Kumanogoh   +20 more
wiley   +1 more source

Metagenomic and Metabolomic Profiling Reveals the Impact of High-Fat Diet on Malignant Pleural Effusion. [PDF]

Thorac Cancer
Chen QY, Shao MM, Dong SF, Shi HZ, Yi FS.   +4 more
europepmc   +1 more source

Clinical Features and Predictive Risk Factors for Prognosis in Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis

The Clinical Respiratory Journal, Volume 20, Issue 4, April 2026.
PM patients exhibit distinctions from IPA in certain clinical characteristics, laboratory parameters, and chest radiology findings. Nevertheless, both PM and IPA patients experienced higher 30‐day mortality and ICU utilization. The combination of NLR and HbA1c with existing disease assessment tools proves effective in prognosticating the disease ...
Yu Bai, Ming Wei, Jun Liu, Xi Chen, Li Gu, Yinqun Guo   +5 more
wiley   +1 more source

The Diagnosis and Treatment of Lung Cancer: Methods, evidence and guidance [PDF]

, 2005
Belchamber, C.A., National Collaborating Centre for Acute Care,   +1 more
core